Actively Recruiting

Phase 2
Age: 0 - 18Years
All Genders
ID03243019

Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis

Led by University Hospital, Lille · Updated on 2026-05-22

28

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University Hospital, Lille

Lead Sponsor

M

Ministry of Health, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of Rapamycin to treat extended cervicofacial lymphatic malformations in children and adolescents up to 18 years old. This Phase 2 study aims to measure how well Rapamycin reduces the volume of these malformations, improves quality of life, and decreases bleeding when mucosal areas are involved. The treatment outcomes are assessed by MRI scans and clinical evaluations over time. Participants receive Rapamycin orally for a period of 6 months. The study monitors response rates at 3 months and continues to observe clinical symptoms and quality of life impacts up to 12 months. Biological tests measure Rapamycin levels and side effects are tracked monthly throughout one year. MRI imaging is used to measure the malformation volume and follow treatment effectiveness. During the study, participants undergo regular clinical assessments and complete Pediatric Quality of Life Inventory (PedsQL 4) scales at baseline, 3, 6, and 12 months. Blood tests evaluate biological responses and safety. Researchers monitor side effects monthly for one year to ensure participant safety. The total follow-up lasts at least one year, allowing detailed tracking of treatment effects and participant well-being.

CONDITIONS

Brief Title

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

Who Can Participate

Age: 0 - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient aged 0 to 18 years with poly-cystic suprahyoid or mediastinal lymphatic malformation
  • Chronic pain or functional respiratory or swallowing impairment with a CDS score less than 8
  • No possible curative treatment or curative treatment poses high risk of morbidity, mortality, or functional and cosmetic impairment
  • Karnofsky score greater than 50% if over 10 years old, or Lansky score greater than 50% if 10 years old or younger
  • Blood counts and chemistry within specified limits: neutrophils ≥1.0 x 10^9/L, platelets ≥100 x 10^9/L, hemoglobin ≥8 g/dL, bilirubin ≤1.5 ULN, transaminases <2.5 ULN, serum albumin ≥2 g/dL, LDL cholesterol <160 mg/dL, triglycerides <150 mg/dL
  • Negative pregnancy test if relevant
  • Social security affiliation
  • At least 2 months since any previous procedure on the malformation
Not Eligible

You will not qualify if you...

  • Failure to meet inclusion criteria
  • Use of other immunosuppressive therapy or long-term corticosteroids without a 28-day washout
  • Renal failure
  • Liver failure
  • Digestive diseases causing rapamycin malabsorption
  • Uncontrolled or severe infectious disease
  • Use of medications that interfere with or inhibit CYP3A4 enzyme activity or use of cisapride and metoclopramide
  • Concurrent use of mTOR inhibitors
  • Allergy to peanuts or soya
  • Inability to provide informed consent
  • No social security affiliation
  • Refusal to sign consent or participate
  • Ongoing pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 12 months

Participants receive oral rapamycin to treat cervico-facial lymphatic malformations and have periodic assessments including MRI and biological dosage of rapamycin levels.

Monthly visits for rapamycin side effect monitoring and assessments at baseline, 3, 6, and 12 months

Trial Site Locations

Total: 2 locations

1

Hôpital Jeanne de Flandres, CHU

Lille, France

Actively Recruiting

2

Hu Robert Debre Aphp - Paris

Paris, France

Actively Recruiting

Loading map...

Research Team

P

Pierre Fayoux, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Prospective Randomized Controlled Study on the Treatment o...

Lymphatic Malformation

Actively Recruiting

1 location

A Modular Open Label, Signal Seeking, Phase II Trial of Targ...

Slow-Flow Vascular Malformation

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here